HKSE - Delayed Quote HKD

Akeso, Inc. (9926.HK)

81.500 -2.000 (-2.40%)

At close: October 30 at 4:08:07 PM GMT+8

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Anthropic’s historic IPO; Akeso’s big clinical showing

Pharma Voice 12h ago

ANTH.PVT

9926.HK
-2.40%
Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

PR Newswire 11d ago

9926.HK
-2.40%
SMMT
Is Akeso (SEHK:9926) A Bargain Following Its New Phase III Colon Cancer Trial?

Simply Wall St. 20d ago

9926.HK
-2.40%
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer

PR Newswire 20d ago

9926.HK
-2.40%
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026

PR Newswire 1mo ago

9926.HK
-2.40%
Akeso (SEHK:9926) Stock Still Looks Cheap Despite Its 141% Run

Simply Wall St. 1mo ago

9926.HK
-2.40%
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China

Business Wire 1mo ago

9926.HK
-2.40%
SMMT
Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC

PR Newswire 1mo ago

9926.HK
-2.40%
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

PR Newswire 2mo ago

9926.HK
-2.40%
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Zacks 2mo ago

9926.HK
-2.40%
AZN

MRK
Akeso logs Phase III success in second tumour type for ivonescimab

Clinical Trials Arena 2mo ago

9926.HK
-2.40%
SMMT

AZN
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

Business Wire 2mo ago

9926.HK
-2.40%
SMMT

Performance Overview

Return	9926.HK	HANG SENG INDEX (^HSI)
YTD	-27.94%	-9.11%
1-Year	-26.51%	-11.37%
3-Year	+88.44%	+33.83%

U.S. markets closed

Akeso, Inc. (9926.HK)

Anthropic’s historic IPO; Akeso’s big clinical showing

Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

Is Akeso (SEHK:9926) A Bargain Following Its New Phase III Colon Cancer Trial?

First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer

Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026

Akeso (SEHK:9926) Stock Still Looks Cheap Despite Its 141% Run

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC

Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Akeso logs Phase III success in second tumour type for ivonescimab

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China